97% of patients who received the BIM-IOL System off all topical IOP-lowering therapy at 12-months100% of BIM-IOL System patients achieved 20/32 or better BCDVA and a mean BCDVA equivalent to 20/20 vision, demonstrating high quality of vision, performance in line with the state-of-the-art IOLs in the control groupOverall safety results were comparable to routine cataract surgery ALISO VIEJO, Calif., March 09, 2026 (GLOBE NEWSWIRE) -- SpyGlass Pharma, Inc. (Nasdaq: SGP) (SpyGlass Pharma), a late-stage biophar ...

ALISO VIEJO, Calif., March 04, 2026 (GLOBE NEWSWIRE) -- SpyGlass Pharma, Inc. (Nasdaq: SGP) (“SpyGlass Pharma”), a late-stage biopharmaceutical company, today announced that members of the executive management team will host 1x1 meetings at the Jefferies Biotech on the Bay Summit in Miami Beach, Florida on Wednesday, March 11, 2026. About SpyGlass Pharma SpyGlass Pharma is a late-stage biopharmaceutical company dedicated to transforming the treatment paradigm for patients living with chronic eye conditions ...

Core Insights - Insider buying has been observed in four notable companies: KKR, Reddit, SpyGlass Pharma, and Veradermics, indicating management's confidence in their future prospects [1] Group 1: Insider Buying Activity - SpyGlass Pharma saw significant insider purchases, with RA Capital Management acquiring approximately 3.7 million shares and NEA adding 937,500 shares at the IPO price of $16.00 per share [1] - Veradermics had Suvretta Capital Management purchase 282,700 shares at a weighted average price of about $36.50, totaling $10.5 million, reflecting a nearly 20% increase in their stake over six months [1] - Reddit's director bought 50,500 shares between $139.11 and $150.00, totaling nearly $7.5 million, marking one of the first major purchases post-IPO lock-up [1] - KKR's director purchased 50,000 shares at prices ranging from $104.36 to $107.10, totaling over $5.2 million, amidst a 22.5% stock retreat in the past month [1] Group 2: Company Performance and Analyst Sentiment - SpyGlass Pharma's stock is trading near $28.20, above the IPO price, with analysts giving a Strong Buy consensus due to its potential in the $5 billion glaucoma market [1] - Veradermics received an Overweight rating from Wells Fargo following successful Phase 3 trial enrollment, with shares currently at $43.46, reflecting a 19% gain for insiders [1] - Reddit's stock is currently at $139.65, with analysts remaining bullish on its high-margin data licensing deals despite recent volatility [1] - KKR reported record assets under management exceeding $740 billion, with analysts optimistic about private equity firms benefiting from the IPO market reopening [1]

ALISO VIEJO, Calif., Feb. 09, 2026 (GLOBE NEWSWIRE) -- SpyGlass Pharma, Inc. (Nasdaq: SGP) (“SpyGlass Pharma”), a late-stage biopharmaceutical company, today announced the closing of its initial public offering of 10,781,250 shares of its common stock, which includes the exercise in full of the underwriters’ option to purchase 1,406,250 additional shares of its common stock, at a public offering price of $16.00 per share. The aggregate gross proceeds from the offering were $172.5 million, before deducting u ...

Group 1: IPO Market Overview - Last week, 7 IPOs and 6 SPACs were priced, with 5 IPOs and 5 SPACs filing for listings [1] - Veradermics raised $256 million with a market cap of $612 million, focusing on a non-hormonal treatment for hair loss [1] - Forgent Power Solutions priced its IPO at $1.5 billion, achieving a market cap of $8.2 billion, with a valuation of 24 times its 2026 EBITDA [1] Group 2: Company-Specific Highlights - Bob's Discount Furniture raised $331 million with a market cap of $2.3 billion, pricing at about 8 times its 2027 EBITDA [2] - Once Upon a Farm raised $198 million with a market cap of $811 million, despite being in a loss position [2] - SpyGlass Pharma raised $150 million with a market cap of $549 million, focusing on chronic eye disease treatments [2] Group 3: Additional IPOs and SPACs - AgomAb Therapeutics raised $200 million with a market cap of $875 million, targeting fibrotic diseases [3] - Eikon Therapeutics raised $381 million with a market cap of $1 billion, led by former Merck executives [3] - Six SPACs completed pricing, including Hennessy Capital VIII raising $210 million [4] Group 4: Upcoming IPO Filings - Five companies filed for IPOs, including Generate Biomedicines seeking $100 million for asthma treatments [8] - Salspera aims to raise $50 million for cancer therapies [8] - Several SPACs also filed for IPOs, including MOZAYYX Acquisition seeking $250 million [8]

Group 1 - The core viewpoint of the article highlights significant stock movements in the Hong Kong and US markets, driven by strategic partnerships, positive financial reports, and market trends [1][2][3][4][5][6][7]. Group 2 - Ocean Group (01991) saw a surge of over 13.3% after announcing a strategic partnership with CONSCIOUSNESS FOUNDATION LTD. to establish a joint venture focused on AI smart hardware, marking a significant step in its AI strategy [1]. - Gaming stocks continued to rise, with Melco International Development (00200) up 5.49% and Sands China (01928) up 3.26%, supported by a 24% year-on-year increase in Macau's gaming revenue for January [1]. - China Energy Storage (02399) increased by over 9.2% following its announcement to acquire 100% of Wuzhong Ruichu Technology for RMB 64 million [2]. - The real estate sector showed recovery, with Sunac China (01918) rising 8.2% as market confidence improved in January [3]. - Gold stocks collectively rose, with China’s gold reserves increasing to 74.19 million ounces, marking a continuous increase for 15 months [4]. - In the US market, Lexin Fintech (LX.US) rose 6.04% amid a broader market rally, with the Dow Jones reaching a historic high of 50,115.67 points [5]. - SpyGlass Pharma (SGP.US) debuted on the US market with a 65% increase, focusing on chronic eye disease treatments [6]. - Bitcoin-related stocks rebounded significantly, with Strategy (MSTR.US) up 26.11% [7].

本文源自：金融界AI电报 SpyGlassPharma(SGP.US)登陆美股市场，现涨超45%，报23.31美元。 ...

智通财经APP获悉，周五，SpyGlass Pharma(SGP.US)登陆美股市场，开盘股价暴涨超43%，报23美元， IPO价格为16美元。SpyGlass Pharma 是一家临床后期生物技术公司，专注于开发 用于慢性眼部疾病的 持续药物输送系统，旨在通过更长效、可持续的治疗方案改善患者的视力和生活质量。其核心研发产品 包括一种将药物输送垫与人工晶状体结合的系统，用于治疗像 开角型青光眼或眼压高 等慢性眼病。这 类治疗目标是提高疗效和患者依从性，与传统每日滴眼药水相比有潜在优势。 ...

周五，SpyGlass Pharma(SGP.US)登陆美股市场，开盘股价暴涨超43%，报23美元，IPO价格为16美元。 SpyGlass Pharma是一家临床后期生物技术公司，专注于开发用于慢性眼部疾病的持续药物输送系统， 旨在通过更长效、可持续的治疗方案改善患者的视力和生活质量。其核心研发产品包括一种将药物输送 垫与人工晶状体结合的系统，用于治疗像开角型青光眼或眼压高等慢性眼病。这类治疗目标是提高疗效 和患者依从性，与传统每日滴眼药水相比有潜在优势。 ...

Company Overview - SpyGlass Pharma, Inc. is a late-stage biopharmaceutical company focused on transforming treatment for patients with chronic eye conditions through long-acting, sustained drug delivery of approved medicines [5] - The company was founded in 2019 by Malik Y. Kahook, M.D. and Glenn Sussman to address the lack of ophthalmic innovations that utilize durable treatment options [7] Initial Public Offering (IPO) Details - SpyGlass Pharma announced the pricing of its initial public offering of 9,375,000 shares at a public offering price of $16.00 per share, aiming for aggregate gross proceeds of approximately $150 million [1] - The underwriters have a 30-day option to purchase up to an additional 1,406,250 shares at the initial public offering price [1] - The common stock is expected to begin trading on the Nasdaq Global Select Market under the ticker symbol "SGP" on February 6, 2026, with the offering expected to close on February 9, 2026 [1] Underwriters and Regulatory Information - Jefferies, Leerink Partners, Citigroup, and Stifel are acting as joint book-running managers for the offering [2] - A registration statement for the offering was filed with the Securities and Exchange Commission and became effective on January 30, 2026 [3]